Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 2 sales; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Climb Bio, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −2 vs. Q4 2023
- Shares held
- 16.9M
- +1.69K (0.0%) vs. Q4 2023
- Total value
- $46.2M
- +$689.2K (+1.5%) vs. Q4 2023
- New holders
- 1
- 6 more added
- Sold out
- 3
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLYM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 108 | $734.3M |
| Q1 2026 | 80 | $221.2M |
| Q4 2025 | 65 | $157.4M |
| Q3 2025 | 68 | $89.7M |
| Q2 2025 | 69 | $61.9M |
| Q1 2025 | 76 | $63.4M |
| Q4 2024 | 80 | $100.3M |
| Q3 2024 | 71 | $278.2M |
| Q2 2024 | 47 | $354.8M |
| Q1 2024 | 21 | $46.2M |
| Q4 2023 | 23 | $45.5M |
| Q3 2023 | 23 | $44.0M |
| Q2 2023 | 22 | $46.8M |
| Q1 2023 | 19 | $48.4M |
| Q4 2022 | 20 | $61.0M |
| Q3 2022 | 22 | $47.8M |
| Q2 2022 | 29 | $45.7M |
| Q1 2022 | 43 | $146.8M |
| Q4 2021 | 35 | $181.8M |
| Q3 2021 | 32 | $310.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Climb Bio, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13,150,849 | $36.0M | 0.46% | 00.0% | Unchanged |
| BML Capital Management, LLC | 2,193,742 | $6.01M | 4.02% | +13,742+0.6% | Added |
| Driehaus Capital Management LLC | 811,680 | $2.22M | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 310,486 | $850.7K | 0.00% | 00.0% | Unchanged |
| Atom Investors LP | 78,276 | $214.5K | 0.03% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 66,626 | $182.6K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 55,223 | $151.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 43,468 | $119.1K | 0.00% | −5,244−10.8% | Reduced |
| BlackRock Inc. | 30,440 | $83.4K | 0.00% | −705−2.3% | Reduced |
| Tudor Investment Corp Et Al | 29,466 | $80.7K | 0.00% | −24−0.1% | Reduced |
| State Street Corp | 21,700 | $59.5K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 20,106 | $55.1K | 0.00% | +1,683+9.1% | Added |
| Chicago Partners Investment Group LLC | 12,104 | $45.4K | 0.00% | −56−0.5% | Reduced |
| Renaissance Technologies LLC | 10,617 | $29.0K | 0.00% | +14+0.1% | Added |
| Advisor Group Holdings, Inc. | 8,333 | $21.7K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 5,925 | $16.2K | 0.00% | +5,925 | New |
| Tower Research Capital LLC (TRC) | 3,606 | $9.88K | 0.00% | +151+4.4% | Added |
| Morgan Stanley | 1,709 | $4.68K | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 981 | $2.69K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 50 | $137 | 0.00% | +2+4.2% | Added |
| Royal Bank of Canada | 63 | $0 | 0.00% | +27+75.0% | Added |
| Cerity Partners LLC | 0 | $0 | 0.00% | −13,821−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1−100.0% | Sold out |